CClinicalTrials.gg
Status unknownNCT04737681Updated Oct 26, 2022

Influence of Body Weight and Composition on Immune Recovery

An observational study in BMI/Body Composition, sponsored by United States Army Research Institute of Environmental Medicine. Status unknown at 1 site in United States. Open to participants aged 18 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-26.

Sponsored by United States Army Research Institute of Environmental Medicine · Observational

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 39 Years
Sex
All
01

Study summary

Immune dysfunction in individuals with obesity, secondary to chronic inflammation, may have an acute impact on War fighter health and readiness, and subsequent lethality. Indeed, \~51% of military personnel ages 17 or older are overweight, and \~15% have obesity (ranging from 6.4% in the Marine Corps to 18.0% in the Army). In conjunction with in vitro functional tests to assess systemic immune function, the suction blister model is a minimally invasive procedure that allows in vivo assessment of immune function (i.e., skin barrier restoration), and related mechanisms (i.e., pro- and anti-inflammatory cytokine responses at the wound site during the early phases of wound healing), consequent to obesity. We have demonstrated that the blister wound model reliably assesses skin barrier restoration and immune function at the wound site; and that relatively modest sleep disruption degrades immune response at the site of the disrupted skin barrier and delays the initial restoration of the skin barrier. However, our prior work excluded participants with obesity (≥30 kg/m2), since obesity is associated with an altered inflammatory response which may subsequently impact the body's functional response to a skin wound. Prior studies have indicated that immune function and wound healing is perturbed in individuals with obesity versus those without obesity. Existing research mainly relied on blood biomarkers and in vitro tests to assess systemic immune function; however, incorporating the blister wound model permits evaluation of the functional immune response to obesity in addition to local immune response at the wound site. Further, military personnel with obesity may be more physically active than civilians with obesity, which could mitigate the effects of obesity on immune dysfunction. Therefore, the primary aim of this parallel-group study is to utilize a suction blister model and in vitro functional assays to examine differences in immune function between participants without obesity (BMI 18.5-24.9 kg/m2) and with obesity (BMI ≥ 30 kg/m2) and related mechanisms (e.g., local cytokine response at the wound site and circulating markers of inflammation). Research will be conducted in a laboratory environment using males and females with obesity (BMI ≥ 30 kg/m2) compared to normal weight (BMI 18.5-24.9 kg/m2) controls. Participants in the study described herein (n = 50; n = 25 with obesity and n = 25 lean) will undergo baseline testing and a period of dietary surveillance prior to induction of up to eight blisters via suction on participant's forearm, after which time the top layer of blisters will be removed to reveal the dermal layer of skin. The primary outcome measure is initial restoration of the skin barrier (via transepidermal water loss) and additional outcome measures include immune function (e.g., circulating markers of inflammation, cytokines at the blister site, and secretory immunoglobin) and nutrient status. Additionally, to assess the impact of BMI on skeletal muscle inflammation, a subset of volunteers (n = 12 with obesity and n =12 lean) will undergo a single muscle biopsy at the conclusion of skin barrier restoration. Findings from this study will determine if obesity affects the early phases of wound healing and whether further study is warranted, e.g., do stressors exacerbate immune decrements observed in obese individuals, or can nutrition counter-measures mitigate immune decrements given that micronutrient deficiency is common in individuals with obesity.

Read the detailed description

See brief summary above.

02

Conditions studied

  • BMI/Body Composition

Browse trials for

03

In context

Body Weight

1,223 studies on the registry are indexed under Body Weight; 131 are open to participants now.

This study's planned enrollment of 50 is below the median of 140 across 238 observational studies indexed under Body Weight.

Browse Body Weight studies →

Lead sponsor

United States Army Research Institute of Environmental Medicine is the lead sponsor of 67 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The participant population will consist of military personnel (male or female) and civilians. Participants will be matched for both sex and the proportion of participants above and below 30 years of age. Potential participants will be screened for body mass index (BMI), percent body fat and aerobic exercise habits.

Inclusion criteria

  • Are between the ages of 18 (or 17 for military personnel) and 39 (i.e., consistent with the age range of 95% of Active Duty enlisted and 75% of Active Duty officers)
  • Have a Body Mass Index (BMI) in the range of 18.5 to \<25 kg/m2 and have a percent body fat by circumference measurements that meets the Army's max allowable body fat standards for individuals classified as "without obesity"; or have a BMI ≥ 30 kg/m2 and have a percent body fat by circumference measurements that exceeds the Army's max allowable body fat standards for individuals classified as "with obesity" (40).
  • Have been weight stable (+/- 5 lbs.) for the past two months (not including temporary body weight fluctuations due to menstrual cycle) and agree not to attempt to lose or gain weight for the duration of the study;
  • Participate in 120-300 mins of aerobic exercise over the course of at least 3 days per week as indicated by self-report data and confirmed during the study via actigraphy (i.e., consistent with the self-reported exercise habits of a majority of active duty military personnel) (1, 41)
  • Are willing to participate in all study procedures and comply with all study instruction.
  • Females must have normal menstrual cycles between 26-32 days in duration; 5 menstrual cycles within the past 6 months; or able to provide documentation of oral/hormonal contraceptive use which contains low-dose estrogen/progesterone to maintain continuous levels throughout the 28-day cycle (i.e., no placebos)
  • Pass a general medical clearance.

Exclusion criteria

Exclusion Criteria:

  • have a tattoo on both forearms that obscures the forearms and doesn't allow space for the suction blister induction;
  • experienced more than a \~5 lbs. weight gain or loss in the last month than is not transient (e.g., menstrual).
  • participate in more than 300 minutes of aerobic exercise per week as indicated by self-report data and confirmed during the study via actigraphy (i.e., consistent with self-reported exercise habits of \~20% of active duty military personnel) (1, 41).
  • are habitually taking nonsteroidal anti-inflammatory drugs (e.g., Advil), aspirin, lipid-lowering drugs, corticosteroids or immunosuppressants (e.g. Humira);
  • are immune-compromised (e.g., chemotherapy or radiation treatment);
  • are suffering from an autoimmune disease (e.g., lupus);
  • recovering from a surgery within the past 6 months;
  • Current doctor-diagnosed and/or treated diabetes, hypertension or dyslipidemia
  • are suffering from sleep apnea;
  • smoke, dip, chew or vape tobacco or nicotine-containing products.
  • regularly (more than 2 days per week) sleep less than 7 hours or more than 9 hours per night; or, take a nap 3 or more days per week.
  • Pregnant or lactating
  • problems with blood clotting (in the subset of participants receiving muscle biopsies only)
  • allergy to lidocaine (in the subset of participants receiving biopsies only)

Females Only:

  • Have abnormal menstrual cycles (not between 26-32 days in duration; or not 5-6 menstrual cycles within the past 6 month) or those that have had an intrauterine device (IUD) placed with the last month or removed within the past 3 months.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Normal BMI

    BMI 18.5-24.9 kg/m2

    Other: body composition

  • Obese BMI

    BMI ≥ 30 kg/m2

    Other: body composition

Interventions

  • Otherbody composition

    This is an observational study to determine immune response and skin barrier restoration in individuals with and without obesity.

06

What researchers measure

Primary outcomes

  1. Initial restoration of the skin barrier

    initial restoration of the skin barrier (via transepidermal water loss)

    Time frame: 4-10 days

Secondary outcomes

  1. circulation markers of inflammation

    Interleukin (IL) 6, IL8, tumor necrosis factor alpha, c-reactive protein

    Time frame: baseline

  2. cytokines at the wound site

    Interleukin (IL) 6, IL8, IL10, tumor necrosis factor alpha

    Time frame: 72 hours

  3. mucosal immune function

    mucosal immune function will be measured via salivary secretory immunoglobulin A

    Time frame: baseline

Other outcomes

  1. nutrient status

    vitamin C, iron and vitamin D status measured from blood

    Time frame: baseline

07

Study locations

1 of 1 sites recruiting
  • U.S. Army Research Institute of Environmental Medicine
    Natick, Massachusetts 01760, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04737681
Lead sponsor
United States Army Research Institute of Environmental Medicine
Responsible party
Sponsor
First posted
Feb 4, 2021
Start date
Sep 1, 2020
Primary completion
Dec 2023 (estimated)
Completion
Sep 2024 (estimated)
Last update
Oct 26, 2022

Study contacts

Tracey J Smith, PhD, RD
Contact
Tracey.smith10.civ@health.mil
508-206-2390

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion